Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + ivonescimab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
cadonilimab + ivonescimab + chemotherapy is an investigational combination regimen developed by Akeso Biopharma for the treatment of recurrent ovarian cancer. This therapeutic approach utilizes two first-in-class bispecific antibodies: cadonilimab (AK104), which simultaneously targets the immune checkpoints PD-1 and CTLA-4, and ivonescimab (AK112), which targets PD-1 and the angiogenic factor VEGF-A. By combining these biologics with standard chemotherapy, the regimen aims to provide a synergistic effect through dual checkpoint inhibition and anti-angiogenesis, potentially overcoming the immunosuppressive tumor microenvironment characteristic of advanced ovarian malignancies. The combination is currently being evaluated in Phase 2 clinical trials to assess its efficacy and safety in patients with recurrent disease.
- Brand names
- Kaitani
- Other names
- cadonilimabivonescimabAK104 and AK112 and Chemotherapy combinationAK-104 and AK112 and Chemotherapy combinationAK 104 and AK112 and Chemotherapy combination
02
Targets
VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA
Beyond the preview
Go deeper on cadonilimab + ivonescimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + ivonescimab + chemotherapy.